Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Reports $11.2M Second-Quarter Gain

NEW YORK, July 21 (GenomeWeb News) - Affymetrix today posted total revenues of $79.8 million for the second quarter of 2004, compared to $68.6 million for Q2 of 2003.

 

The company said that $1.4 million of its second-quarter revenue was related to the sales of products and wafers to Perlegen Sciences. In Q2 of 2003, Affymetrix said that $2.8 million of its revenue was related to Perlegen sales.

 

Affymetrix reported revenues of $35.4 million on sales of its GeneChip microarrays and $20.1 million on instruments. The company said it increased its installed base of GeneChip systems to approximately 1,070.

 

The company also reported a net income of $7 million in Q2 of 2004, as compared to $5.2 million in the same quarter last year. R&D expenditures rose to $17.8 million for the second quarter from $16.6 million in Q2 of 2003.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.